Metastatic biomarker discovery through proteomics

Cancer Genomics and Proteomics

Volumn 9, Issue 6, 2012, Pages 345-356

  Brinton, Lindsey T ^a   Brentnall, Teresa A ^b   Smith, Jeffrey A ^a   Kelly, Kimberly A ^a  

^a University of Virginia   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarker; Cancer; Imaging agent; Mass spectroscopy (MS); Metastasis; Metastatic potential; Personalized medicine; Prognosis; Proteomics; Recurrence; Review

Indexed keywords

ALPHA ENOLASE; ALPHAVBETA6 INTEGRIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CHAPERONIN 60; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALECTIN 1; GROWTH DIFFERENTIATION FACTOR 15; HEAT SHOCK PROTEIN 27; INTERLEUKIN 6; INTERLEUKIN 8; MUCIN 1; OSTEONECTIN; PLECTIN; PROTEIN AGR2; PROTEIN AGR3; PROTEIN EMP2; PROTEOME; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA1; TRIOSEPHOSPHATE ISOMERASE; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1;

BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; COLORECTAL CANCER; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; HUMAN; KIDNEY CANCER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS; NASOPHARYNX CANCER; OVARY CANCER; PANCREAS CANCER; PERSONALIZED MEDICINE; PROSTATE CANCER; PROTEOMICS; REVIEW; UTERINE CERVIX CANCER;

EID: 84869751778     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Weigelt B, Peterse JL and van't Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602, 2005.
2. Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304, 2002.
3. Chen R, Pan S, Aebersold R and Brentnall T: Proteomics studies of pancreatic cancer. Proteomics Clin Appl 1: 1582-1591, 2007.
4. Caprioli RM, Farmer TB and Gile J: Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69: 4751-4760, 1997.
5. Issaq HJ, Veenstra TD, Conrads TP and Felschow D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292: 587-592, 2002.
6. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 96: 353-356, 2004.
7. Fan J, Deng X, Gallagher JW, Huang H, Huang Y, Wen J, Ferrari M, Shen H and Hu Y: Monitoring the progression of metastatic breast cancer on nanoporous silica chips. Philos Transact A Math Phys Eng Sci 370: 2433-2447, 2012.
8. Xue H, Lu J, Zhang J, Wu M, Huang Q, Wu Q, Sheng H, Wu D, Hu J and Lai M: Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 9: 545-555, 2010.
9. Grønborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen O, Hruban R, Goggins M, Maitra A and Pandey A: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5: 157-171, 2006.
10. Weng L, Wu C, Hsu B, Chi L, Liang Y, Tseng C, Hsieh L and Yu J: Secretome-based identification of mac-2 binding protein as a potential oral cancer marker involved in cell growth and motility. J Proteome Res 7: 3765-3775, 2008.
11. Lou X, Xiao T, Zhao K, Wang H, Zheng H, Lin D, Lu Y, Gao Y, Cheng S, Liu S and Xu N: Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J Proteome Res 6: 1083-1092, 2007.
12. Ghosh D, Yu H, Tan XF, Lim TK, Zubaidah RM, Tan HT, Chung MCM and Lin Q: Identification of key players for colorectal cancer metastasis by iTRAQ quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. J Proteome Res 10: 4373-4387, 2011.
13. Pan S, Aebersold R, Chen R, Rush J, Goodlett DR, McIntosh MW, Zhang J and Brentnall TA: Mass spectrometry based targeted protein quantification: methods and applications. J Proteome Res 8: 787-797, 2009.
14. Katayama M, Nakano H, Ishiuchi A, Wu W, Oshima R, Sakurai J, Nishikawa H, Yamaguchi S and Otsubo T: Protein pattern difference in the colon cancer call lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry. Surg Today 36: 1085-1093, 2006.
15. Zhao L, Liu L, Wang S, Zhang YF, Yu L and Ding YQ: Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol 133: 771-782, 2007.
16. Hoffman RM: Clinical Practice. Screening for prostate cancer. N Engl J Med 365: 2013-2019, 2011.
17. Gambert SR: Prostate cancer. When to offer screening in the primary care setting. Geriatrics 56: 29-31, 2001.
18. Shariat SF, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J and Wheeler TM: Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20: 833-841, 2002.
19. Shariat SF, Karam JA, Margulis V and Karakiewicz PI: New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJUI 101: 675-683, 2008.
20. 1 and Interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 10: 1992-1999, 2004.
21. Cho WSC, Yip TTC, Yip C, Tip V, Thulasiraman V, Ngan RKC, Yip T, Lau W, Au JSK, Law SCK, Cheng W, Ma VWS and Lim CKP: Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10: 43-52, 2004.
22. Diamandis EP: Letter to the Editor about Identification of serum amyloid protein as a potentially useful biomarker for nasopharyngeal carcinoma. Clin Cancer Res 10: 5293, 2004.
23. Li J, Xie Z, Shi L, Zhao Z, Hou J, Chen X, Cui Z, Xue P, Cai T, Wu P, Guo S and Yang F: Purification, identification and profiling of serum amyloid A proteins from sera of advanced-stage cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci 15: 889-890, 2012.
24. Rosenthal CJ and Sullivan LM: Serum amyloid A to monitor cancer dissemination. Ann Intern Med 91: 383-390, 1979.
25. Biran H, Friedman N, Neumann L, Pras M and Shainkin-Kestenbaum R: Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39: 794-797, 1986.
26. Raynes JG and Cooper EH: Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol 36: 798-803, 1983.
27. Pierce BL, Neuhouser ML, Wener MH, Bernstein L, Baumgartner RN, Ballard-Barbash R, Gilliland FD, Baumgartner KB, Sorensen B, McTiernan A and Ulrich CM: Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors. Breast Cancer Res Treat 114: 155-167, 2009.
28. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA and Flad T: Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84: 845-856, 2004.
29. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V and Clynes M: Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer, 2011 [Epub ahead of print].
30. Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol 39: 1553-1558, 2011.
31. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA and Sadar MD: Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51: 695-707, 2005.
32. Sasazuki S, Inoue M, Sawada N, Iwasaki M, Shimazu T, Yamaji T and Tsugane S: Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study. J Carcinog 31: 712-718, 2010.
33. Autelitano DJ, Raineri L, Knight K, Bannister K and Rice GE: Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. J Transl Med 10: 45, 2012.
34. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O'Briant K, Drescher C and Urban N: Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 102: 26-38, 2010.
35. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P and Rice GE: Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 136: 1079-1088, 2010.
36. Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G and Dogliotti L: Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 30A: 2082-4, 1994.
37. Tampellini M, Berruti A, Torta M, Buniva T, Raucci CA and Dogliotti L: CA 125 in advanced breast cancer (BC). A sensitive marker for lung involvement and significant predictor for survival. Eur J Cancer 29: S248, 1993.
38. Wen CL, Chen KY, Chen CT, Chuang JG, Yang PC and Chow LP: Development of an AlphaLISA assay to quantify serum core-fucosylated E-cadherin as a metastatic lung adenocarcinoma biomarker. J Proteomics, 2012 [Epub ahead of print].
39. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HFM, Oosterhof GON, Debruyne FMJ and Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929-3933, 1994.
40. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takasuka Y, Matsuyoshi N, Hirano S, Takeichi M and Mori T: Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53: 1696-1701, 1993.
41. Mayer B, Johnson JP, Leiti F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W and Funke I: E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 53: 1690-1695, 1993.
42. Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T and Kuwano H: Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep pp. 605-611, 2004.
43. Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A and Guerrero JM: CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Clin Lab 57: 1011-1014, 2011.
44. El-Nabi EAA, Gommaa NEE, Zeid AAEA, Kantoush NAA, Ahmed MM and Bushra SS: Evaluation of Cyfra 12-1 as a diagnostic tool in lung cancer. J Appl Sci Res 5: 1195-1201, 2009.
45. Shitrit D, Zingerman B, Shirtit ABG, Shlomi D and Kramer MR: Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of literature. Oncologist 10: 501-507, 2005.
46. Reimel BA, Pan S, May DH, Shaffer SA, Goodlett DR, Mcintosh MW, Yerian LM, Bronner MP, Chen R and Brentnall TA: Proteomics on fixed tissue specimens - a review. Curr Proteomics 6: 63-69, 2009.
47. La Thangue NB and Kerr DJ: Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8: 587-596, 2011.
48. Cabioglu N, Sahin A, Morandi P, Meric-Bernstam F, Islam R, Lin H, Bucana CD, Gonzalez-Angulo AM, Hortobagyi GN and Cristofanilli M: Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20: 1013-1019, 2009.
49. Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE and Sahin A: CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11: 5686-5693, 2005.
50. Liu Y, Ji R, Li J, Gu Q, Zhao X, Sun T, Wang J, Li J, Du Q and Sun B: Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis. J Exp Clin Cancer Res 29: 16, 2010.
51. Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, Yildirim EO, Aktas E, Bilgic S, Kiran B, Deniz G and Price JE: Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 22: 39-46, 2005.
52. Li D, Wang L, Fei F, Hou Y, Luo J, Zeng WR, Wu J, Lu J, Di G, Ou Z, Xia Q, Shen Z and Shao Z: Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6: 3352-3368, 2006.
53. Yoo JY, Yang SH, Lee JE, Cho DG, Kim HK, Kim SH, Kim IS, Hong JT, Sung JH, Son BC and Lee SW: E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by piogliatazone in a preclinical model. J Neurooncol, 2012 [Epub ahead of print].
54. Chen D, Zhang Y, Zhang X, Li J, Han B, Liu S, Wang L, Ling Y, Mao S and Wang X: Overexpression of integrin-linked kinase correlates with malignant phenotype in non-small cell lung cancer and promotes lung cancer cell invasion and migration via regulating epithelial-mesenchymal transition (EMT)-related genes. Acta Histochem, 2012 [Epub ahead of print].
55. Folkman J: What is the evidence that tumours are angiogenesis-dependent? J Natl Cancer Inst 82: 4-6, 1990.
56. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR and Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964-3968, 1995.
57. Lebrecht A, Ludwig E, Huber A, Klein M, Schneeberger C, Tempfer C, Koelbl H and Hefler L: Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol Oncol 85: 32-5, 2002.
58. Juttner S, Wißmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schalg PM, Kemmner W and Hocker M: Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. JCO 24: 228-240, 2006.
59. White JD, Hewett PW, Kosuge D, McCulloch T, Enholm BC, Carmichael J and Murray JC: Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res 62: 1669-75, 2002.
60. Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, Okuda H and Kudo T: Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 35: 485-9, 1999.
61. Poon RTP, Lau CPY, Cheung ST, Yu WC and Fan ST: Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 63: 3121-3126, 2003.
62. Jacobsen J, Rasmuson T, Grankvist K and Ljungberg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163: 343-347, 2000.
63. Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K and Sekiya S: Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 103: 724-730, 2005.
64. Baritaki S, Sifakis S, Huerta-Yepez S, Neonakis IK, Soufla G, Bonavida B and Spandidos DA: Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. Int J Oncol 31: 69-79, 2007.
65. Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin L, D'Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, O'Reilly EM and Allen PJ: A novel survival-based tissue microarray of pancreatic cancer identifies clinical useful candidate biomarkers. PLoS One 7: e40157, 2012.
66. Pérez-Torras S, Garcia-Manteiga J, Mercade E, Casado FJ, Carbo N, Pastor-Anglada M and Mazo A: Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 76: 322-329, 2008.
67. Manuyakorn A, Paulus R, Farrell J and Dawson DW: Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28: 1358-1365, 2010.
68. Chen R, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, Lane Z, Post J, Bronner MP, Willmann JK, Maitra A and Brentnall TA: Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic adenocarcinoma. Cancer Biol Ther 13: 899-907, 2012.
69. Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KA, Grutzmann R, Aust D, Rummele P, Knosel T, Herd C, Stemple DL, Kettleborough R, Brosnan JA, Li A, Morgan R, Knight S, Yu J, Stegeman S, Collier LS, ten Hoeve JJ, de Ridder J, Klein AP, Goggins M, Hruban RH, Chang DK, Biankin AV, Grimmond SM; Australian Pancreatic Cancer Genome Initiative, Wessels LF, Wood SA, Iacobuzio-Donahue CA, Pilarsky C, Largaespada DA, Adams DJ and Tuveson DA: The deubiquintinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 486: 266-270, 2012.
70. Slack-Davis JK, Atkins KA, Harrer C, Hershey ED and Conaway M: Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 69: 1469-1476, 2009.
71. Gray TA, MacLaine NJ, Michie CO, Bouchalova P, Murray E, Howie J, Hrstka R, Maslon MM, Nenutil R, Vojtesek B, Langdon S, Hayward L, Gourley C and Hupp TR: Anterior gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. J Immunol Methods 378: 20-32, 2012.
72. Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA, Daviet L, Legrain P, Parekh R, Harris AL and Terrett JA: hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer 88: 579-585, 2003.
73. Park K, Chung YJ, So H, Kim K, Park J, Oh M, Jo M, Choi K, Lee E, Choi Y, Song SY, Bae D, Kim B and Lee J: AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med 43: 91-100, 2011.
74. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavvers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM and Wong K: The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol 35: 904-912, 2011.
75. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S and Sauter ER: Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 10: 7500-7510, 2004.
76. Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN and Schmitt P: Prediction of lung cancer using volatile biomarkers in breath. Cancer biomark 3: 95-109, 2007.
77. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M and Creasman WT: Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A. Gynecol Oncol 98: 467-483, 2005.
78. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, Kim RY, Saria MG, Pastorino S, Kesari S and Krichevsky AM: MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro Oncol 14: 689-700, 2012.
79. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA and Wong DT: Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 14: 6246-6252, 2008.
80. Bausch D, Mino-Kenudson M, Fernandez-Del Castillo C, Warshaw AL, Kelly KA and Thayer SP: Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms. J Gastrointest Surg 13: 1948-1954, 2009.
81. Hoffman P, Ji H, Moritz RL, Connolly LM, Frecklington DF, Layton MJ and Eddes JS, Simpon: Continuous free-flow electrophoresis separation of cytosolic proteins from the human colon carcinoma cell line LIM 1215L: a non two-dimensional gel electrophoresis-based proteome analysis strategy. Proteomics 7: 807-818, 2001.
82. McKinney KQ, Lee YY, Choi HS, Groseclose G, Iannitti DA, Martinie JB, Russo MW, Lundgren DH, Han DK, Bonkovsky HL and Hwang SI: Discovery of putative pancreatic cancer biomarkers using subcellular proteomics. J Proteomics 74: 79-88, 2011.
83. Smith GP and Petrenko VA: Phage display. Chem Rev 97: 391-410, 1997.
84. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J and Soslow RA: Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 107: 90-98, 2006.
85. Fu M, Brewer S, Olafsen T, Wu AM, Gordon LK, Said J, Braun J and Wadehra M: Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments. Mol Imaging Biol, 2012. [Epub ahead of print].
86. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK and Wadehra M: Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res 14: 7367-7377, 2008.
87. Hausner SH, Abbey CK, Bold RJ, Gagnon MK, Marik J, Marshall JF, Stanecki CE and Sutcliffe JL: Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. Cancer Res 69: 5843-5850, 2009.
88. Bausch D, Thomas S, Mino-Kenudson M, Fernandez-del Castillo C, Bauer TW, Williams M, Warshaw AL, Thayer SP and Kelly KA: Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res 17: 302-309, 2011.
89. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, Goodman SL, Kosmahl M and Kloppel G: Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 45: 226-236, 2004.
90. Li S, McGuire MJ, Lin M, Liu YH, Oyama T, Sun X and Brown KC: Synthesis and characterization of a high-affinity {alpha}v{beta} 6-specific ligand for in vitro and in vivo applications. Mol Cancer Ther 8: 1239-1249, 2009.
91. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P and Mercurio AM: Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115: 339-3347, 2005.
92. Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM, Weinreb PH and Fleuren GJ: Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol 212: 316-324, 2007.
93. 6 expression with positron emission tomography. Cancer Res 67: 7833-7840, 2007.
94. Pysz MA and Willmann JK: Targeted contrast-enhanced ultrasound: an emerging technology in abdominal and pelvic imaging. Gastroenterology 140: 785-790, 2010.
95. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR and Gambhir SS: Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 51: 433-440, 2010.
96. Gloss BS and Samimi G: Epigenetic biomarkers in epithelial ovarian cancer. Cancer Let, 2012 [Epub ahead of print].
97. Thomas S, Waterman P, Chen S, Marinelli B, Seaman M, Rodig S, Ross RW, Josephson L, Weissleder R and Kelly KA: Development of secreted protein and acidic and rich in cysteine (SPARC) targeted nanoparticles for the prognostic molecular imaging of metastatic prostate cancer. J Nanomed Nanoechnol 2: 112, 2011.